BiliaryTractCancer near Rego Park, NY

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: I realize how scary it can be to receive a life-threatening diagnosis, and firmly believe in taking the time to clearly communicate with my patients about the nature of their disease and their various treatment options. This can not only vastly improve our patients' experiences, but also their treatment outcomes, as an educated patient is able to make informed decisions about care and reclaim some of the autonomy that can be lost when coping with a cancer diagnosis. In the midst of all the cutting-edge science and technology that we offer, I find it extremely important to remember that it is the patient who is the center of it all. I genuinely care about my patients, and instilling a sense of hope, sharing a laugh, or a kind word can be as important as all the medical advances and state-of-the-art science.

Biography: Jones Nauseef, M.D., Ph.D., is an Assistant Professor of Medicine within the Division of Hematology and Medical Oncology at Weill Cornell Medicine, and Assistant Attending physician at NewYork-Presbyterian Hospital. His clinical emphasis is on Genitourinary (GU) cancers and Phase I clinical trials. His research is focused on genomics of advanced prostate cancers, including neuroendocrine prostate cancer, as well as health care disparities.Dr. Nauseef received his B.A. in Biology in 2006 from Swarthmore College, where he also participated in NCAA Track and Cross Country. In 2015, Dr. Nauseef earned his M.D. and Ph.D. in Molecular Physiology and Biophysics (Laboratory of Dr. Michael D. Henry) as part of the NIH-sponsored MedicalScientist Training Program (MSTP) at the Carver College of Medicine of theUniversity of Iowa. He continued his medical training at Weill Cornell Medicine and NewYork-Presbyterian (WCM/NYP), where he completed his Internship and Residency in Internal Medicine in 2018. He was honored to be the recipient of the David B. Skinner award at the conclusion of his residency. He remained at WCM/NYP for his Fellowship in Hematology and Medical Oncology, during which time he was awarded a 2020 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) and the 2021 Scott Wadler Fellows Clinical Research Award. During his Fellowship, Dr. Nauseef expanded his research focus to include the genomics of advanced prostate cancers and health care disparities in American men of African descent. He serves as co-investigator or collaborator on extramural grants for the latter project. Dr. Nauseef will continue these investigations as a member of the Englander Institute for Precision Medicine and inaffiliation with the New York Genome Center, with the primary goal of leveraging discoveries to develop clinical trials as part of the Phase I/Earlytherapeutics group at Weill Cornell's Meyer Cancer Center.

Biography: Dr. Winchell is an internationally renowned expert in care of the critically injured and the development, design, and operation of trauma systems. He is the G. Thomas Shires II Professor of Surgery, Professor of Medical Ethics in Medicine, and Chief of the Division of Trauma, Burns, Acute and Critical Care at Weill Cornell Medicine. He heads one of the leading Level 1 trauma centers in New York City and oversees the internationally recognized William Randolph Hearst Burn Center.Dr. Winchell received his undergraduate degree at the California Institute of Technology, his M.D. from Yale University, and did his internship, General Surgery residency, and Trauma and Critical Care Fellowship at the University of California, San Diego. He is board certified in general surgery, with added qualifications in surgical critical care. He served on the faculty at UCSD as Associate Professor of Clinical Surgery until 1999, and prior to joining Weill Cornell, he was a Visiting Professor of Surgery at the University of Texas Health Science Center in Houston and Chief of Trauma at Memorial Hermann-Texas Medical Center.Dr. Winchell is a fellow of the American College of Surgeons, currently serving as Governor for the Manhattan Council Chapter. He served on the American College of Surgeons Committee on Trauma for over 20 years, in various roles including Chair of the Trauma Systems Evaluation and Planning Committee, member of the Executive Committee, and Special Consultant for International Quality Programs. Dr Winchell has led the development and evolution of trauma systems throughout the world, including his seminal work in the Committee on Trauma's Trauma System Consultation Program, and work with the WHO Global Alliance for the Care of the Injured.Dr. Winchell is the author of more than 100 scientific papers and book chapters, and has given over 200 regional, national, and international presentations. He is an associate editor of the Journal of Trauma and Acute Care Surgery, a section editor for the European Journal of Trauma, and reviewer for several other journals including Trauma and Acute Care Surgery Open, the Archives of Surgery, and the World Journal of Surgery. He is a fellow or member of the American Surgical Association, the American Association for the Surgery of Trauma, the American Burn Association, the New England Surgical Society, the International Society for Surgery, the International the Association for Trauma Surgery and Intensive Care, the Western Trauma Association, and the Society of Critical Care Medicine as well as other national and regional scholarly societies.

Care Philosophy: Today's research and treatment of lung cancer are at the cutting edge of science and technology. Enormous progress has been made in lung cancer treatment. Several targeted therapies and now immunotherapies have changed the way we treat the disease. Cancer patients and their families who come to the Lombardi Comprehensive Cancer Center will work closely with a team of dedicated and knowledgeable cancer specialists to determine the most appropriate treatment path for their specific cancer needs. My research is focused on advancing our understanding of lung cancer and thymic tumors and their responses to specific treatment, including how to harness the body's immune system to fight cancer. I keep my patients and their families front and center in my practice to help them understand the technology that may be available to them. My goal is to always work together with my patients, using science to overcome disease.

Biography: Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. As a key opinion leader in three different types of genitourinary cancers, Dr. Sternberg isknown for her influential work in developing novel therapies and targeted agents for the treatment of prostate, renal and bladder cancers.Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. These treatments are the gold standard, saving many lives and decreasing suffering in patientswith these diseases.Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Most recently, her publication in the New England Journal of Medicine (NEJM) demonstrated dramatic improvements in metastasis-free survival (MFS) in men with castration resistant prostate cancer (CRPC) without evidence of metastatic disease, but at high risk of developing metastases, a population for whom there were previously no approved therapeutics. This research led to the approval of enzalutamide in the M0 CRPC patient population.Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. Dr. Sternberg served as lead investigator in the large phase 3 international study that demonstrated the efficacy, safety and tolerability of this drug in patients with metastatic kidney cancer, culminating in the FDA approval. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer.At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. AsClinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens. In addition to providing her clinical and research expertise in genitourinary oncology, Dr. Sternberg will work closely with Olivier Elemento, PhD, renowned computational biologist and Director of the EIPM, to develop novel strategies and apply precision oncology to optimize cancer prevention, detection and treatment across a variety of tumor types.Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center.Dr. Sternberg has published approximately 400 articles in peer-reviewed publications,including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks atprestigious international venues.Throughout her career, she has served on the editorial boards of Critical Reviews in Hematology and Oncology, Annals of Oncology, and the Journal of Clinical Oncology, and she currently serves on the editorial boards of Oncology, European Urology, the Harvard Medical School Annual Report on Prostate Diseases, Kidney Cancer, Nature Clinical Practice Urology, and European Urology Oncology. Dr. Sternberg also serves as Reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Lancet Oncology and others.She currently serves as the Solid Tumor Editor for Critical Reviews in Hematology and Oncology, Section Editor for Urologic Oncology, Associate Editor for Bladder Cancer Clinical Trials Corner, Associate Editor and Genitourinary Oncology Editor for ESMO Open-Cancer Horizons, and Associate Editor for Frontiers in Oncology. Additionally, Dr. Sternberg previously served as Oncology Editor for the British Journal of Urology, Section Editor for Urologic Oncology, and Genitourinary Editor for the European Journal of Cancer.Dr. Sternberg's leadership in the field is further exemplified by the numerous international committees on which she has served. She was elected to three consecutive terms as Board Member and Executive Board Member of the European Organization for Research and Treatment of Cancer (EORTC) and elected to the nominating committee of the American Society of Clinical Oncology (ASCO) board of directors, currently serving a 3-year term.This document has been edited with the instant web content composer which can be found at htmleditor.tools - give it a try.

Biography: Cassandra Villegas, MD MPH is an Attending Surgeon at Weill Cornell Medical Center in the Division of Trauma, Burns, Critical, and Acute Care Surgery. She received her B.S. in Biological Sciences from Stanford University, where she was a President' Scholar and received the Teaching Excellence award. She remained at Stanford University as an instructor and doing neuroscience research before joining Teach for America to teach high school science in Los Angeles Unified School District for five years. There, she won the Most Inspirational Teacher Award before leaving education to attend Johns Hopkins School of Medicine. As a medical student, she completed her MPH at Columbia University Mailman School of Public Health, focusing on data outcomes research while diversifying her medical training at Guy's, King's, and St. Thomas's Hospital in London, England as well as the Royal College of Surgeons in Dublin, Ireland.She continued her outcomes research in trauma and health disparities before starting her general surgery residency at the University of Arizona. While there, she took 1st Place in the American College of Surgeons Resident Paper Competition and earned the American Association for the Surgery Resident Scholarship for her work her in trauma outcomes. She received Resident Educator of the Year twice, and was Awarded Resident of the Year at the Southern Arizona Veteran's Hospital. At the conclusion of her residency, she was awarded the Charles Putnam Chief Resident Teaching Award.Dr. Villegas then completed her Surgical Critical Care and Acute Care Surgery Fellowships at New York-Presbyterian Weill Cornell Medical College in New York, where she now serves as faculty and continues her research interest in trauma, emergency surgery, and global health surgery. She is a member of the American College of Surgeons, the Easter Association for the Surgery of Trauma, and the Surgical Outcomes Society.

Biography: Nima Maghami, MD FACS is an Assistant Professor of Surgery in Weill Cornell Medicine's Division of Trauma, Burns, Acute and Critical Care Surgeryand an Assistant Attending Surgeon at New York-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Maghami earned his B.S. degree, magna cum laude, in Physiology and Neurobiology from University of Maryland. Subsequently, he received his medical degree from the Medical College of Wisconsin where he obtained the Distinguished Medical Student Research Award for his work on transplantation immune tolerance induction. He then completed his internship and residency training in General Surgery at Albany Medical College, in Albany, NY followed by fellowship training in Surgical Critical Care atNew York-Presbyterian/Weill Cornell Medical Center. After obtaining his dual board certifications in General Surgery and Surgical Critical Care, he joined the faculty at Houston Methodist Hospital as an acute care surgeon and surgical intensivist. Having a strong passion for medical education, Dr. Maghami has mentored numerous medical students and residents over the years. As an Assistant Professor of Surgery at Texas A&M College of Medicine, he had the opportunity to be involved in medical education and curriculum development. Dr. Maghami's efforts in medical education and distinction as a clinician-educator have been recognizedby both students and residents. He won the Best Faculty for Surgery Award by Texas A&M College of Medicine students for two years consecutively, in 2019 and 2020. In addition, he won the prestigious Golden Apple Faculty Teaching Award given by the general surgery residents at the Houston Methodist Hospital in 2020 as well as the Faculty Award for Outstanding Service by the hospital that year. By being a member of various medical organizations and global outreach programs, Dr. Maghami strives to be part of a collaborative team advancing medical care and advocating for patient care nationally and internationally.

Biography: John Ng, M.D.is a Board Certified Radiation Oncologist and Assistant Professor of Radiation Oncology at Weill Cornell Medical College/New York Presbyterian Hospital. As a native New Yorker, he received his undergraduate degree in Physics at Columbia University.He went to medical school at Harvard and also received a Master of Science degree in Biophysics from Harvard University. He received his M.D. degree from Harvard Medical School, jointly with the Massachusetts Institute of Technology, as part of the Health Sciences and Technology (HST) program. He returned to New York City and the Columbia University Medical Center for his residency training in Radiation Oncology, where he also served as a chief resident. He joined the Weill Cornell Medical Center as faculty, where he serves as attending physician for Breast Oncology and for Gastrointestinal Oncology. His most recent awards include the Faculty Educator of the Year Award from the Weill Cornell New York-Presbyterian Residency Program, a RSNA Roentgen Research Award, an ASCO Research Travel Award, and a NCCN Travel Grant.Dr. Ng was recently appointed the Chair of the Radiation Oncology Section of New York Roentgen Society, the only scientific group that congregates radiation oncologists in the New York Metropolitan area and is comprised of leaders in the fields of diagnostic radiology and radiation oncology. He also currently serves as a Program Committee member for the American Association for Cancer Research (AACR), serves on the Economics Committee of the American College of Radiation Oncology (ACRO), and is an active Program Committee member of the New York Metropolitan Breast Cancer Group.Areas of Specialization:Breast Cancer, Gastrointestinal Cancers, Breast Intraoperative Radiotherapy, Breast Balloon Brachytherapy, Pancreatic Cancer, Sarcoma, Stereotactic Body Radiotherapy (SBRT).Research:Dr. Ng's research is focused on developing novel radiation techniques that can reduce treatment side effects and improve outcomes. One area of particular focus is developing partial breast radiotherapy techniques to treat less breast tissue with less radiation to reduce side effects and to shorten treatment times.Another research interest is advancing radiotherapy technologies to treat pancreatic cancer. He is currently writing a textbook review on Gastrointestinal and Hepatobiliary Radiation Therapy and working on a review on minimizing malignancy risks after radiation therapy.He is also actively involved in the development of new drugs and agents to use with radiotherapy to improve cure rates for breast cancer and gastrointestinal cancers. Presently, his group is collaborating with others in developing skin products to decrease skin side effects from breast radiotherapy.

Biography: Dr. Paul Pagnini has served as a leader in community-based and academic radiation oncology for the past 20 years. Dr. Pagnini completed his residency training in Radiation Oncology at Tufts/New England Medical Center where he was chief resident in his final year. He was awarded the prestigious Research Fellowship Award from the American Society of Therapeutic Radiation Oncology, which enabled him to study the role of intensity modulated radiation therapy (IMRT) for the treatment of cancers of the central nervous system. He has served on the Faculty of the University of Southern California, Keck School of Medicine where he was the Radiation Oncology Residency Program Director. His most recent position was with the Cleveland Clinic Florida, where he served as Department Chair for the last five years. He has multiple peer reviewed publications in the areas of intensity modulated radiation therapy (IMRT), 3-D conformal radiation therapy, Cyberknife, and Gamma-Knife radiosurgery.

Biography: Dr. Encouse Golden, MD is a Radiation Oncology Specialist who practices in New York, NY. He has been practicing for 16 years. Dr. Encouse Golden, MD is affiliated with Weill Cornell Medical Center.